Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Biosino Bio-Technology and Science (HKSE:08247) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Biosino Bio-Technology and Science EBITDA Margin % Related Terms
Biosino Bio-Technology and Science EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biosino Bio-Technology and Science EBITDA Margin % Chart
HKSE:08247 vs TMO, DHR, IDXX: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, Biosino Bio-Technology and Science's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biosino Bio-Technology and Science EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Biosino Bio-Technology and Science's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Biosino Bio-Technology and Science's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biosino Bio-Technology and Science (HKSE:08247) has a EBITDA Margin % of -47.68% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Biosino Bio-Technology and Science and its competitors. According to the industry distribution chart, Biosino Bio-Technology and Science ranks #148 out of 202 companies in the Medical Diagnostics & Research industry, placing it in the top 73.3%.
Is Biosino Bio-Technology and Science's EBITDA Margin % too high?
Biosino Bio-Technology and Science's current EBITDA Margin % is -47.68%. Based on the distribution chart, Biosino Bio-Technology and Science ranks #148 out of 202 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Biosino Bio-Technology and Science has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biosino Bio-Technology and Science's EBITDA Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Biosino Bio-Technology and Science ranks #148 out of 202 companies for EBITDA Margin %. This places Biosino Bio-Technology and Science in the lower half of its industry. The industry median EBITDA Margin % is 5.22. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.22, based on 202 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Biosino Bio-Technology and Science and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biosino Bio-Technology and Science's current EBITDA Margin % is -47.68%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biosino Bio-Technology and Science stock overvalued right now?
Based on GuruFocus' analysis, Biosino Bio-Technology and Science (HKSE:08247) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.44, compared to a current price of HK$3.17 — trading 619.3% above its estimated fair value. The current EBITDA Margin % is -47.68%. Biosino Bio-Technology and Science's overall GF Score™ is 37/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Biosino Bio-Technology and Science (HKSE:08247), the current EBITDA Margin % is -47.68% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biosino Bio-Technology and Science (HKSE:08247) Overvalued in 2026?
Based on GuruFocus' analysis, Biosino Bio-Technology and Science stock appears to be overvalued.
The current stock price of HK$3.17 is trading 619.3% above its estimated GF Value™ of HK$0.44.
GuruFocus considers Biosino Bio-Technology and Science to be Significantly Overvalued.
Key valuation signals for HKSE:08247:
EBITDA Margin %: -47.68%
GF Value™: HK$0.44 vs. price of HK$3.17 (619.3% above fair value)
No single metric tells the full story. See the HKSE:08247 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biosino Bio-Technology and Science Inc is engaged in the manufacture, sale, and distribution of IVD reagent products. The company operates in a single segment, the in-vitro diagnostic products segment, which manufactures, sells, and distributes a variety of mono/double diagnostic products. Geographically, it generates the majority of the revenue from Mainland China.
37GF Score
Get the complete analysis for HKSE:08247
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:08247 has been successfully added to your 
